These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 33538152)

  • 21. Efficacy of the GMALL-B-ALL/NHL2002 protocol in Burkitt leukemia/lymphoma and aggressive non-Hodgkin-lymphomas with or without CNS involvement.
    Sakarou M; Eisele L; Dührsen U; Hüttmann A
    Eur J Haematol; 2019 Mar; 102(3):241-250. PubMed ID: 30471148
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prospective study of Burkitt lymphoma treatment in adolescents and adults in Malawi.
    Painschab MS; Westmoreland KD; Kasonkanji E; Zuze T; Kaimila B; Waswa P; El-Mallawany NK; Tomoka T; Mulenga M; Montgomery ND; Fedoriw Y; Gopal S
    Blood Adv; 2019 Feb; 3(4):612-620. PubMed ID: 30796065
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diffuse large B-cell lymphoma with testicular involvement: outcome and risk of CNS relapse in the rituximab era.
    Kridel R; Telio D; Villa D; Sehn LH; Gerrie AS; Shenkier T; Klasa R; Slack GW; Tan K; Gascoyne RD; Connors JM; Savage KJ
    Br J Haematol; 2017 Jan; 176(2):210-221. PubMed ID: 27739058
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis.
    Barnes JA; Lacasce AS; Feng Y; Toomey CE; Neuberg D; Michaelson JS; Hochberg EP; Abramson JS
    Ann Oncol; 2011 Aug; 22(8):1859-64. PubMed ID: 21339382
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study.
    Mead GM; Sydes MR; Walewski J; Grigg A; Hatton CS; Pescosta N; Guarnaccia C; Lewis MS; McKendrick J; Stenning SP; Wright D;
    Ann Oncol; 2002 Aug; 13(8):1264-74. PubMed ID: 12181251
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens.
    Oosten LEM; Chamuleau MED; Thielen FW; de Wreede LC; Siemes C; Doorduijn JK; Smeekes OS; Kersten MJ; Hardi L; Baars JW; Demandt AMP; Stevens WBC; Nijland M; van Imhoff GW; Brouwer R; Uyl-de Groot CA; Kluin PM; de Jong D; Veelken H
    Ann Hematol; 2018 Feb; 97(2):255-266. PubMed ID: 29209924
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Secondary central nervous system involvement in 599 patients with diffuse large B-cell lymphoma: are there any changes in the rituximab era?
    Deng L; Song Y; Zhu J; Zheng W; Wang X; Xie Y; Lin N; Tu M; Ping L; Ying Z; Liu W; Zhang C
    Int J Hematol; 2013 Dec; 98(6):664-71. PubMed ID: 24234713
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and tolerability of chemotherapy in Chinese patients with AIDS-related Burkitt lymphoma and diffuse large B-cell lymphoma: An observational study.
    Xiao J; Du S; Dai G; Gao G; Yang D; Zhao H
    Sci Rep; 2017 May; 7(1):1905. PubMed ID: 28507339
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Burkitt leukaemia/lymphoma: R-CODOX-M/R-IVAC remains gold standard treatment in BL.
    Smyth L; Browne PV; Conneally E; Flynn C; Hayden P; Jeffers M; O'Brien D; Quinn F; Kelly J; Perera M; Crotty GM; Leahy M; Hennessy B; Jackson F; Ryan M; Vandenberghe E
    Ir J Med Sci; 2016 Nov; 185(4):773-777. PubMed ID: 25843016
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure.
    Ayers EC; Li S; Medeiros LJ; Bond DA; Maddocks KJ; Torka P; Mier Hicks A; Curry M; Wagner-Johnston ND; Karmali R; Behdad A; Fakhri B; Kahl BS; Churnetski MC; Cohen JB; Reddy NM; Modi D; Ramchandren R; Howlett C; Leslie LA; Cytryn S; Diefenbach CS; Faramand R; Chavez JC; Olszewski AJ; Liu Y; Barta SK; Mukhija D; Hill BT; Ma H; Amengual JE; Nathan S; Assouline SE; Orellana-Noia VM; Portell CA; Chandar A; David KA; Giri A; Hess BT; Landsburg DJ
    Cancer; 2020 Jan; 126(2):293-303. PubMed ID: 31568564
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Central nervous system relapse in peripheral T-cell lymphomas: a Swedish Lymphoma Registry study.
    Ellin F; Landström J; Jerkeman M; Relander T
    Blood; 2015 Jul; 126(1):36-41. PubMed ID: 25957393
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of central nervous system prophylaxis with stand-alone intrathecal chemotherapy in diffuse large B-cell lymphoma patients treated with anthracycline-based chemotherapy in the rituximab era: a systematic review.
    Eyre TA; Djebbari F; Kirkwood AA; Collins GP
    Haematologica; 2020 Jul; 105(7):1914-1924. PubMed ID: 31488560
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial.
    Ribrag V; Koscielny S; Bosq J; Leguay T; Casasnovas O; Fornecker LM; Recher C; Ghesquieres H; Morschhauser F; Girault S; Le Gouill S; Ojeda-Uribe M; Mariette C; Cornillon J; Cartron G; Verge V; Chassagne-Clément C; Dombret H; Coiffier B; Lamy T; Tilly H; Salles G
    Lancet; 2016 Jun; 387(10036):2402-11. PubMed ID: 27080498
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Asian variant of intravascular large B-cell lymphoma: a comparison of clinical features based on involvement of the central nervous system.
    Yoon SE; Kim WS; Kim SJ
    Korean J Intern Med; 2020 Jul; 35(4):946-956. PubMed ID: 31752477
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of rituximab on incidence of and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: a systematic review and meta-analysis.
    Zhang J; Chen B; Xu X
    Leuk Lymphoma; 2014 Mar; 55(3):509-14. PubMed ID: 23741977
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Highly elevated serum lactate dehydrogenase is associated with central nervous system relapse in patients with diffuse large B-cell lymphoma: Results of a multicenter prospective cohort study.
    Kim SJ; Hong JS; Chang MH; Kim JA; Kwak JY; Kim JS; Yoon DH; Lee WS; Do YR; Kang HJ; Eom HS; Park Y; Won JH; Mun YC; Kim HJ; Kwon JH; Kong JH; Oh SY; Lee S; Bae SH; Yang DH; Jun HJ; Kim YS; Yun HJ; Lee SI; Kim MK; Park EK; Kim WS; Suh C
    Oncotarget; 2016 Nov; 7(44):72033-72043. PubMed ID: 27713132
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcomes of HIV-associated Burkitt Lymphoma in Brazil: High treatment toxicity and refractoriness rates - A multicenter cohort study.
    Silva WFD; Garibaldi PMM; Rosa LID; Bellesso M; Clé DV; Delamain MT; Rego EM; Pereira J; Rocha V
    Leuk Res; 2020 Feb; 89():106287. PubMed ID: 31864677
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical Effect of CD25 on the Prognosis of Diffuse Large B Cell Lymphoma with Secondary Central Nervous System Relapse.
    Oka S; Ono K; Nohgawa M
    Pathol Oncol Res; 2020 Jul; 26(3):1843-1850. PubMed ID: 31768966
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Elevated LDH and paranasal sinus involvement are risk factors for central nervous system involvement in patients with peripheral T-cell lymphoma.
    Yi JH; Kim JH; Baek KK; Lim T; Lee DJ; Ahn YC; Kim K; Kim SJ; Ko YH; Kim WS
    Ann Oncol; 2011 Jul; 22(7):1636-1643. PubMed ID: 21220520
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
    Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
    Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.